| INTRODUC TI ON

New-onset diabetes mellitus after transplantation (NODAT) is a serious complication following solid organ transplantation (SOT)
1 affecting 2%-53% of transplanted patients. 2 It is considered that NODAT alone is associated with increased 3-year mortality and a significant reduction in graft survival. 2 NODAT is also associated with increased cardiovascular events, infectious complications, and graft loss, 3 which justifies the great interest in understanding the underlying mechanisms and risk factors contributing to the development of this disease. Obesity, increased age, hepatitis C virus (HCV) infection, family history of diabetes mellitus, and African-American or Hispanic descent are among the risk factors of NODAT. 4 Immunosuppressive drugs such as corticosteroids and calcineurin inhibitors, in particular tacrolimus, are also associated with an increased risk of NODAT.
1,2
Both infections and NODAT are frequent complications in SOT and may be related to altered innate immune responses. 5 The innate immune system is the first line of defense against infections with offending pathogens. Cytokines released from immune cells can elicit local and systemic inflammatory responses that can contribute to the development of type 2 diabetes mellitus by enhancing insulin resistance. Several proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interferon gamma (IFNγ), were previously shown to decrease the expression of insulinsensitive glucose transporters, insulin signaling, and to promote insulin resistance. 6 Also, in the absence of infection, obesity (pre-and posttransplant) is associated with chronic low-grade inflammation driven by adipokines derived from adipose tissue, which can lead to insulin resistance 7 and the development of NODAT. Genome-wide association studies conducted to date explain only 10% of type 2 diabetes mellitus heritability and more diabetes mellitus susceptibility genes remain to be discovered. 9 Regarding the genetics of NODAT, little is known and many inconsistent associations have been reported and are reviewed. 10 Therefore, we aimed to examine whether single nucleotide polymorphisms (SNPs) located in different genes mainly implicated in inflammation or in the immune responses to infectious diseases may contribute to the development of NODAT in SOT recipients. As control, analyses were extended to samples of the general population. 
| MATERIAL S AND ME THODS
| Second replication SOT sample
A full description of this cohort is published elsewhere. [12] [13] [14] Briefly, Overall, 1294, 759, and 200 patients from the STCS discovery sample, the first STCS replication sample, and the second SOT replication sample, respectively, were included in the study. After excluding patients younger than 18 years of age, patients with multiple organ transplantation, patients with previous diabetes mellitus or prediabetes mellitus, and keeping patients with both clinical and genetic data available, 696, 489, and 156 patients, respectively, remained included in the NODAT analysis.
| Population-based samples
Significant SNPs were tested for association with diabetes mellitus and with different metabolic parameters in the Cohorte Lausannoise (CoLaus, n = 5338) were also tested. More information is given in the Supporting Information.
| Polymorphism selection
Two hundred eighty-seven SNPs within 158 different genes (Table S1) implicated in the immune response to infectious pathogens or inflammation were selected from customized 384 Golden Gate Genotyping Assay (Ilumina, San Diego, CA). More information about Polymorphism selection and genotyping is given in the Supporting Information.
| Statistical analyses
Quantitative data are presented as median and range unless otherwise mentioned, while qualitative data are presented as frequency and percentage. For association studies, the χ 2 test or the Fisher exact test for binomial variables were used. Differences in allele and genotype frequencies as well as deviation from Hardy-Weinberg equilibrium (HWE) were assessed using the χ 2 test. Data were analyzed using Stata 13 (StataCorp, College Station, TX) and R version 2.13.0 software (http://www.R-project.org).
| STCS samples (discovery and first replication sample)
NODAT in the STCS samples was analyzed using logistic regression models adjusted for recipient's age at transplantation, sex, HCV status, baseline body mass index (BMI), and the type of calcineurin inhibitor (variables identified through the univariate analysis with P < .10, Table 1 ). Associations between NODAT and selected SNPs with P < .01 in the STCS discovery sample were retained and analyzed in the STCS replication sample and in other cohorts as described. No correction for multiple testing was applied for the discovery sample because it was only used to explore associations between the selected SNPs and NODAT, and these associations were only considered significant if replicated in another cohort.
Bonferroni correction for multiple testing, however, was applied for the replication cohorts.
In the combined STCS sample, logistic regression models adjusted for recipient's age at transplantation, sex, and baseline BMI were used to analyze other metabolic parameters including newonset hyperlipidemia after transplantation. Because of nonlinearity of BMI and HDL-cholesterol models and the absence of any linear transformation, the association between the SNPs with BMI and HDL-cholesterol levels was assessed by fitting a generalized additive mixed model (GAMM) to allow a smooth trend for the response in time based on multiple observations for each patient (using a thin plate regression spline basis) adjusting for recipient's age at transplantation, sex, and baseline BMI (also adjusted for the use of hypolipidemic drugs for analysis of HDL-cholesterol). GAMMs were fitted using the mgcv package of R (settings were fixed at package defaults). In order to be more conservative, the uncertainty of estimated parameters was assessed by 1000 bootstraps at the subject level. Linear mixed models were used for total blood cholesterol and LDL-cholesterol analyses. These models were adjusted for recipient's age at transplantation, sex, baseline BMI, and hypolipidemic drug intake.
| Second replication SOT sample
Logistic regression models were applied for NODAT analyses adjusted for recipient's age at transplantation, sex, baseline BMI, and type of calcineurin inhibitors. 
| Population-based samples
| RE SULTS
| General characteristics of the study populations
The incidence of NODAT in the discovery sample was 21.8%.
NODAT patients were older with higher baseline BMI and were more often prescribed tacrolimus-based maintenance immunosuppression compared to non-NODAT patients. A detailed description of this sample is presented in Table 1 . Similar descriptions for the replication samples are presented in Tables S2 and S3 .
| Polymorphisms in immune-related genes and NODAT in the STCS and the replication samples
The minor allele frequency was <5% for 12 SNPs in our discovery sample and they were removed from the analyses. Additionally, 12
SNPs did not meet HWE (P < .05); therefore, a total of 263 SNPs were finally analyzed (Table S1 , Parts A, B, and C). Among these SNPs, 10 polymorphisms were associated with NODAT (P < .01 in additive models and/or allele dosage; Table S4 ). These SNPs were used for replication in the first replication sample (second subset of the STCS sample).
Among these 10 SNPs only 1 SNP, the SP110 nuclear body protein (SP110) rs2114592C>T, was associated with NODAT in the first replication sample after correction for multiple testing ( 
006). Time to NODAT in the combined STCS sample
by SP110 genotype is shown in Figure 1 , with an increased incidence of NODAT during the first year in SP110 rs2114592-TT genotype carriers (P = .003) compared to other genotypes.
A second SNP (rs2907749A>G) within the nucleotide-binding oligomerization domain containing 1 (NOD1) was associated with
NODAT in the discovery and in the first replication samples, but this association did not remain significant after multiple testing correction (Table S5a ). This SNP was not significantly associated with NODAT in the second SOT replication sample (data not shown), but was significantly associated with NODAT (n = 1156), new-onset hyperlipidemia (n = 1051), lower HDL-cholesterol (n = 1051), and higher total cholesterol levels (n = 1051) in the combined STCS sample (Table S5a and 5b).
| SP110 rs2114592C>T SNP and other metabolic syndrome complications in the combined STCS sample
The associations between SP110 rs2114592C>T SNP and other met- (Table S6 ).
| SP110 rs2114592C>T SNP and metabolic markers in population-based samples
In the population-based samples, SP110 rs2114592C>T SNP was not associated with the different metabolic markers investigated, including available diabetes mellitus markers (Table S7 ).
| Tagging SNPs of SP110 gene
Twenty-six tagging SNPs within the SP110 gene were found using HapMap Genome Browser (Table S8) 
| Estimation of the functional activity of SP110 rs2114592C>T SNP
The functional activity of SP110 rs2114592C>T SNP was investigated using the RegulomeDB database. 17 We found 22 SNPs to be in complete linkage disequilibrium (r 2 = 1) with SP110 rs2114592C>T SNP (intronic variant), among them the SP110 rs75411703 SNP, which shows a deoxyribonuclease sensitivity quantitative trait loci (dsQTL) effect and is linked to the expression of the target gene. 18 Additionally, by using the eQTL gene browser-gene network database,
rs2114592-T allele is associated with a decrease of SP110 expression in the blood (P = 3.87E-26). Altogether, these data suggest that SP110
rs2114592C>T SNP might have important regulatory functions.
| D ISCUSS I ON
Inflammation is intimately linked with the development of diabetes mellitus in the general population (reviewed in refs. 20, 21) and recipients of SOT. 5 In our study, 10 polymorphisms within 10 different genes primarily implicated in the innate immune response or inflammation were significantly (P < .01) associated with NODAT in a discovery cohort of 696 patients from the STCS without a previous history of diabetes mellitus or glucose intolerance before SOT. (1193) 24 (897) 36 (414) 48 (31) E2-alpha (encoded by TCF3). TCF3 is a transcriptional regulator that binds to IEB1 and IEB2, which are short DNA sequences in the insu- 15 which is a strength in our study.
Even though the association between SP110 rs2114592C>T and NODAT was replicated in 2 cohorts, they are modest in size and not truly independent. The present finding must therefore be confirmed by future studies. The selection of the SNPs was based on SNPs already associated with infections and inflammation in the literature and does not cover all variants within these genes, so unknown variants within these candidate genes with important associations with NODAT or novel pro-inflammatory variants may have been missed.
Our findings on samples in white subjects cannot be extrapolated to other ethnicities. The present results do not allow determining whether SP110 rs2114592C>T SNP is the causative variant or merely a proxy of 1 or more yet unidentified variants. Despite the important regulatory functions suggested by the RegulomeDB and the eQTL databases, further studies are needed to elucidate which precise mechanisms underlie the observed associations. Another limitation is the low allelic frequency of SP110 rs2114592C>T with only few homozygote carriers of TT genotype being observed (Table S9) . Thus, SP110 rs2114592C>T contributes only to a small fraction of newonset diabetes mellitus in the analyzed populations. On the other hand, the fact that these results were replicated in 2 independent samples with SOT strengthens the validity of our data. In addition, the high observed ORs suggest important clinical implications of SP110 rs2114592C>T SNP. Well-designed prospective clinical trials should therefore be conducted to test whether genetic testing before transplantation may offer more precise new-onset diabetes mellitus risk stratification. In addition, SP110 may be even more relevant in predicting diabetes mellitus in specific subgroups of at-risk SOT patients (eg, HCV-infected transplant recipients or overweight patients), but this remains to be analyzed.
In conclusion, our results link for the first time the SP110 gene in the development of diabetes mellitus and other metabolic complications in SOT recipients. While the pathway by which the SP110 rs2114592C>T SNP is associated with diabetes mellitus remains undetermined, our study opens the door for further investigation of this SNP and provides a promising new candidate gene for diabetes mellitus development. Ultimately, an important question will be to determine whether personalized strategies based on genetic testing in pretransplant patients may help to reduce the risk of developing diabetes mellitus.
